Page last updated: 2024-11-01

ondansetron and Lupus Erythematosus, Cutaneous, Subacute

ondansetron has been researched along with Lupus Erythematosus, Cutaneous, Subacute in 1 studies

Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Yung, RL1
Richardson, BC1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
[NCT00004643]Phase 210 participants Interventional1995-02-28Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Other Studies

1 other study available for ondansetron and Lupus Erythematosus, Cutaneous, Subacute

ArticleYear
Cytarabine therapy for refractory cutaneous lupus.
    Arthritis and rheumatism, 1995, Volume: 38, Issue:9

    Topics: Adult; Antimetabolites, Antineoplastic; Cytarabine; Drug Therapy, Combination; Female; Humans; Lupus

1995